Navigation Links
Prenatal Alcohol Exposure Sets Cognitive Problems After 10 Years

Heavy alcohol intake by pregnant women can even lead to Fetal Alcohol Syndrome. Especially during the second trimester drinking can cause significant deficit// in the IQ of the offspring-Report of recent analysis.

· African-American rather than Caucasian offspring are more prone to this condition.

Although deficits in measures of intelligence are well documented among children exposed to high amounts of alcohol during pregnancy, deficits among children prenatally exposed to low-to-moderate amounts of alcohol are much less understood. A study in the June issue of Alcoholism: Clinical & Experimental Research has found that even light to moderate drinking – especially during the second trimester – is associated with lower IQs in offspring at 10 years of age.

‘The impact of heavy prenatal alcohol exposure on IQ ranges from a two- to a seven-point decrease,’ said Jennifer A. Willford, assistant professor of psychiatry at the University of Pittsburgh School of Medicine and lead author of the study. ‘IQ is a measure of the child's ability to learn and to survive in his or her environment. It predicts the potential for success in school and in everyday life. Although a small but significant percentage of children are diagnosed with Fetal Alcohol Syndrome (FAS) each year, many more children are exposed to alcohol during pregnancy who do not meet criteria for FAS yet experience deficits in growth and cognitive function.’

‘Intellectual functioning is a good first measure of the potential damaging effects of prenatal alcohol exposure,’ added Paul D. Connor, clinical director of the Fetal Alcohol and Drug Unit and assistant professor in the department of psychiatry and behavioral sciences at the University of Washington.‘However, mental retardation only characterizes a minority of patients with FAS and Alcohol-Related Neurodevelopmental Disorder (ARND). There are a number of domains of cognitive functioning that can be impaired even in
'"/>




Page: 1 2 3

Related medicine news :

1. The Safety Of Prenatal Ultrasounds Questioned
2. More Importance To Be Given To Prenatal Nutrition
3. Prenatal exposure to air pollution causes chromosomal damage
4. Personal Growth and Success Dependent on Prenatal Health
5. Prenatal Test and Miscarriage
6. Prenatal multivitamins reduce birth defects
7. Prenatal Multivitamins to prevent risk of Brain Tumors In Kids
8. Simple Blood Test may Replace Invasive Prenatal Tests
9. Hope for Noninvasive Prenatal Test
10. New Approach to Routine Prenatal Genetic Testing
11. Harmful Effects Of Glucocorticoids On Newborns Owing To Prenatal Exposure
Post Your Comments:
Other Medicine News:Health News:Penn talks at ASCB touch on cancer, neurodegenerative diseases, and MD 2Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 2Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 3Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 4Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Emission capture study funded for paper industry 10353 1Emission capture study funded for paper industry 10353 2Emission capture study funded for paper industry 10353 3Fear of being laughed at crosses cultural boundaries 10348 1Fear of being laughed at crosses cultural boundaries 10348 2Fear of being laughed at crosses cultural boundaries 10348 3Fear of being laughed at crosses cultural boundaries 10348 4Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2